 Thomas Flaig
Concepts (382)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 37 | 2024 | 196 | 9.420 |
Why?
| | Prostatic Neoplasms | 36 | 2022 | 921 | 5.960 |
Why?
| | Kidney Neoplasms | 23 | 2023 | 328 | 3.990 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 18 | 2021 | 40 | 3.900 |
Why?
| | Antineoplastic Agents | 28 | 2021 | 1879 | 3.580 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 26 | 2022 | 1353 | 3.540 |
Why?
| | Carcinoma, Renal Cell | 18 | 2023 | 168 | 3.530 |
Why?
| | Carcinoma, Transitional Cell | 12 | 2024 | 54 | 3.350 |
Why?
| | Androgen Antagonists | 14 | 2020 | 69 | 2.660 |
Why?
| | Pyrroles | 7 | 2017 | 181 | 1.720 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 298 | 1.710 |
Why?
| | Indoles | 7 | 2017 | 304 | 1.580 |
Why?
| | Medical Oncology | 5 | 2020 | 227 | 1.480 |
Why?
| | Urologic Neoplasms | 6 | 2023 | 25 | 1.440 |
Why?
| | Neoplasm Metastasis | 24 | 2021 | 524 | 1.400 |
Why?
| | Abiraterone Acetate | 9 | 2021 | 14 | 1.380 |
Why?
| | Urothelium | 3 | 2016 | 33 | 1.340 |
Why?
| | Adenocarcinoma | 7 | 2020 | 795 | 1.190 |
Why?
| | Prednisone | 14 | 2021 | 231 | 1.190 |
Why?
| | Taxoids | 7 | 2017 | 93 | 1.170 |
Why?
| | Phenylurea Compounds | 6 | 2016 | 82 | 1.160 |
Why?
| | Neoplasm Staging | 13 | 2023 | 1169 | 1.130 |
Why?
| | Antineoplastic Agents, Hormonal | 8 | 2017 | 138 | 1.130 |
Why?
| | Mitoxantrone | 5 | 2018 | 12 | 1.120 |
Why?
| | Niacinamide | 5 | 2016 | 62 | 1.070 |
Why?
| | Prostate-Specific Antigen | 11 | 2022 | 151 | 1.060 |
Why?
| | Male | 86 | 2023 | 55735 | 1.040 |
Why?
| | Orchiectomy | 4 | 2014 | 57 | 1.020 |
Why?
| | Cisplatin | 11 | 2024 | 262 | 0.990 |
Why?
| | Humans | 125 | 2024 | 115047 | 0.960 |
Why?
| | Antibodies, Monoclonal, Humanized | 8 | 2024 | 665 | 0.930 |
Why?
| | Penile Neoplasms | 1 | 2023 | 7 | 0.880 |
Why?
| | Aged | 52 | 2022 | 19122 | 0.850 |
Why?
| | Phenylthiohydantoin | 6 | 2021 | 40 | 0.820 |
Why?
| | Carcinoma | 2 | 2016 | 199 | 0.820 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 96 | 0.800 |
Why?
| | ErbB Receptors | 6 | 2018 | 555 | 0.770 |
Why?
| | Treatment Outcome | 28 | 2023 | 9123 | 0.770 |
Why?
| | Immunotherapy | 5 | 2022 | 474 | 0.760 |
Why?
| | Protein Kinase Inhibitors | 6 | 2014 | 787 | 0.750 |
Why?
| | Nitriles | 10 | 2021 | 152 | 0.720 |
Why?
| | Neoplasm Invasiveness | 6 | 2024 | 442 | 0.720 |
Why?
| | Aged, 80 and over | 25 | 2021 | 6357 | 0.710 |
Why?
| | Radiosurgery | 4 | 2015 | 298 | 0.670 |
Why?
| | Disease-Free Survival | 12 | 2017 | 617 | 0.630 |
Why?
| | Bone Neoplasms | 3 | 2015 | 194 | 0.620 |
Why?
| | Sulfonamides | 2 | 2012 | 445 | 0.610 |
Why?
| | Cystectomy | 5 | 2024 | 32 | 0.600 |
Why?
| | Viscera | 2 | 2014 | 13 | 0.600 |
Why?
| | Middle Aged | 41 | 2021 | 26830 | 0.590 |
Why?
| | Hematologic Diseases | 2 | 2016 | 55 | 0.590 |
Why?
| | Prostatectomy | 5 | 2018 | 98 | 0.570 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 152 | 0.570 |
Why?
| | Urinary Bladder | 3 | 2023 | 163 | 0.560 |
Why?
| | Benzamides | 7 | 2021 | 168 | 0.560 |
Why?
| | Erythrocytes, Abnormal | 1 | 2016 | 12 | 0.560 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1398 | 0.560 |
Why?
| | Prognosis | 12 | 2023 | 3334 | 0.550 |
Why?
| | Liver Neoplasms | 3 | 2017 | 516 | 0.550 |
Why?
| | Receptors, Androgen | 2 | 2021 | 131 | 0.520 |
Why?
| | Pancreatitis | 1 | 2016 | 107 | 0.510 |
Why?
| | Genomics | 2 | 2018 | 641 | 0.510 |
Why?
| | Silymarin | 4 | 2013 | 194 | 0.480 |
Why?
| | Leydig Cell Tumor | 1 | 2014 | 8 | 0.460 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2016 | 167 | 0.440 |
Why?
| | Multicenter Studies as Topic | 2 | 2021 | 250 | 0.420 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2023 | 332 | 0.420 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 228 | 0.410 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1523 | 0.410 |
Why?
| | Hypothyroidism | 1 | 2012 | 65 | 0.400 |
Why?
| | Administration, Intravesical | 3 | 2022 | 14 | 0.400 |
Why?
| | Carcinoma, Basal Cell | 1 | 2013 | 68 | 0.400 |
Why?
| | Sarcoma | 1 | 2013 | 137 | 0.400 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 62 | 0.390 |
Why?
| | Therapies, Investigational | 1 | 2011 | 14 | 0.390 |
Why?
| | Diethylstilbestrol | 1 | 2011 | 8 | 0.390 |
Why?
| | Angiomyolipoma | 1 | 2011 | 17 | 0.390 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1268 | 0.380 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 103 | 0.380 |
Why?
| | Pyrazoles | 2 | 2023 | 362 | 0.370 |
Why?
| | Disease Progression | 10 | 2021 | 2389 | 0.370 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2008 | 534 | 0.370 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 59 | 0.370 |
Why?
| | Lung Neoplasms | 5 | 2017 | 2201 | 0.360 |
Why?
| | Androstenes | 4 | 2015 | 11 | 0.360 |
Why?
| | Retrospective Studies | 12 | 2024 | 12548 | 0.350 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 347 | 0.350 |
Why?
| | United States | 10 | 2023 | 12227 | 0.350 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2010 | 63 | 0.350 |
Why?
| | Adult | 25 | 2021 | 30658 | 0.340 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 385 | 0.340 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 616 | 0.340 |
Why?
| | Kaplan-Meier Estimate | 8 | 2016 | 814 | 0.340 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 447 | 0.340 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 52 | 0.340 |
Why?
| | SEER Program | 4 | 2023 | 196 | 0.330 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2010 | 181 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2022 | 856 | 0.330 |
Why?
| | Lymphatic Diseases | 1 | 2009 | 17 | 0.330 |
Why?
| | Neuroblastoma | 1 | 2010 | 132 | 0.320 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2009 | 61 | 0.320 |
Why?
| | Cystitis | 1 | 2009 | 20 | 0.320 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 499 | 0.320 |
Why?
| | Survival Rate | 9 | 2021 | 1646 | 0.320 |
Why?
| | Double-Blind Method | 12 | 2021 | 1665 | 0.310 |
Why?
| | Androstadienes | 3 | 2013 | 97 | 0.310 |
Why?
| | Female | 26 | 2021 | 59617 | 0.310 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2008 | 19 | 0.310 |
Why?
| | Precision Medicine | 1 | 2011 | 340 | 0.310 |
Why?
| | Intestinal Perforation | 1 | 2008 | 38 | 0.310 |
Why?
| | Clinical Trials as Topic | 5 | 2018 | 937 | 0.300 |
Why?
| | Pyrimidines | 1 | 2011 | 376 | 0.300 |
Why?
| | Deoxycytidine | 3 | 2024 | 138 | 0.300 |
Why?
| | Muscles | 3 | 2024 | 324 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 577 | 0.300 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 722 | 0.300 |
Why?
| | Testosterone | 3 | 2021 | 343 | 0.290 |
Why?
| | Survival Analysis | 6 | 2021 | 1211 | 0.280 |
Why?
| | BCG Vaccine | 2 | 2018 | 18 | 0.280 |
Why?
| | Androgen Receptor Antagonists | 3 | 2021 | 30 | 0.280 |
Why?
| | Combined Modality Therapy | 9 | 2020 | 1127 | 0.280 |
Why?
| | Cell Line, Tumor | 7 | 2018 | 2715 | 0.270 |
Why?
| | Nanotubes | 2 | 2018 | 41 | 0.270 |
Why?
| | Quinazolines | 4 | 2019 | 240 | 0.270 |
Why?
| | Neoplasm Grading | 6 | 2018 | 243 | 0.260 |
Why?
| | Carboplatin | 1 | 2006 | 135 | 0.260 |
Why?
| | Gold | 2 | 2018 | 106 | 0.260 |
Why?
| | Skin Neoplasms | 1 | 2013 | 758 | 0.260 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 431 | 0.250 |
Why?
| | Lymphatic Metastasis | 2 | 2018 | 275 | 0.250 |
Why?
| | Gonadotropin-Releasing Hormone | 2 | 2020 | 188 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 636 | 0.250 |
Why?
| | Biomarkers, Tumor | 4 | 2023 | 1045 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1215 | 0.250 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 182 | 0.240 |
Why?
| | Societies, Medical | 2 | 2018 | 678 | 0.240 |
Why?
| | Drug Synergism | 3 | 2011 | 317 | 0.230 |
Why?
| | Dexamethasone | 1 | 2006 | 317 | 0.230 |
Why?
| | Androstenols | 3 | 2015 | 4 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2013 | 1857 | 0.220 |
Why?
| | Tosyl Compounds | 4 | 2018 | 14 | 0.220 |
Why?
| | Drug Administration Schedule | 4 | 2021 | 719 | 0.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1144 | 0.220 |
Why?
| | Vitamin D | 1 | 2006 | 340 | 0.210 |
Why?
| | Steroid 17-alpha-Hydroxylase | 2 | 2014 | 4 | 0.210 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2023 | 26 | 0.210 |
Why?
| | Anilides | 4 | 2018 | 67 | 0.210 |
Why?
| | Quality of Life | 4 | 2024 | 2359 | 0.200 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2024 | 117 | 0.200 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 250 | 0.200 |
Why?
| | Retroperitoneal Space | 1 | 2021 | 15 | 0.200 |
Why?
| | Thiohydantoins | 1 | 2021 | 2 | 0.200 |
Why?
| | Indazoles | 2 | 2012 | 58 | 0.190 |
Why?
| | Tissue Extracts | 2 | 2012 | 20 | 0.190 |
Why?
| | Databases, Factual | 2 | 2016 | 1132 | 0.190 |
Why?
| | Kallikreins | 2 | 2019 | 30 | 0.190 |
Why?
| | Retreatment | 1 | 2021 | 67 | 0.190 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 241 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 4 | 2014 | 2341 | 0.180 |
Why?
| | Time Factors | 5 | 2020 | 6141 | 0.180 |
Why?
| | Genetic Heterogeneity | 1 | 2020 | 49 | 0.170 |
Why?
| | Phosphatidylcholines | 2 | 2013 | 133 | 0.170 |
Why?
| | Angiogenesis Inhibitors | 2 | 2021 | 214 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2011 | 310 | 0.160 |
Why?
| | Yttrium | 1 | 2018 | 5 | 0.160 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 168 | 0.160 |
Why?
| | Fluorides | 1 | 2018 | 43 | 0.160 |
Why?
| | Euterpe | 1 | 2018 | 5 | 0.160 |
Why?
| | Central Nervous System | 1 | 2020 | 238 | 0.160 |
Why?
| | Organ Sparing Treatments | 1 | 2018 | 31 | 0.160 |
Why?
| | Piperidines | 2 | 2010 | 162 | 0.160 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.150 |
Why?
| | Lymph Node Excision | 2 | 2021 | 140 | 0.150 |
Why?
| | Odds Ratio | 1 | 2021 | 957 | 0.150 |
Why?
| | Congresses as Topic | 2 | 2012 | 198 | 0.150 |
Why?
| | Apoptosis | 1 | 2007 | 2366 | 0.150 |
Why?
| | Antioxidants | 2 | 2013 | 530 | 0.150 |
Why?
| | History, 21st Century | 2 | 2015 | 161 | 0.150 |
Why?
| | Tumor Escape | 1 | 2018 | 35 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2019 | 137 | 0.150 |
Why?
| | Genome | 1 | 2020 | 271 | 0.150 |
Why?
| | Neoplasm, Residual | 2 | 2021 | 104 | 0.150 |
Why?
| | Microscopy, Fluorescence | 3 | 2018 | 398 | 0.150 |
Why?
| | Proton Therapy | 1 | 2017 | 10 | 0.140 |
Why?
| | Blotting, Western | 2 | 2010 | 1149 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1178 | 0.140 |
Why?
| | Goserelin | 3 | 2018 | 8 | 0.140 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 27 | 0.140 |
Why?
| | Biopsy | 3 | 2018 | 1046 | 0.140 |
Why?
| | Plant Extracts | 1 | 2018 | 154 | 0.140 |
Why?
| | Aftercare | 1 | 2018 | 186 | 0.140 |
Why?
| | Oligopeptides | 1 | 2018 | 234 | 0.140 |
Why?
| | Dyslipidemias | 1 | 2018 | 154 | 0.140 |
Why?
| | Fatal Outcome | 2 | 2008 | 285 | 0.140 |
Why?
| | Watchful Waiting | 1 | 2016 | 56 | 0.130 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2016 | 68 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 441 | 0.130 |
Why?
| | United States Food and Drug Administration | 1 | 2016 | 172 | 0.130 |
Why?
| | Prostate | 2 | 2021 | 157 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 563 | 0.120 |
Why?
| | Nanoparticles | 1 | 2018 | 313 | 0.120 |
Why?
| | Patient Selection | 1 | 2018 | 646 | 0.120 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 90 | 0.120 |
Why?
| | Radiation Tolerance | 1 | 2015 | 92 | 0.120 |
Why?
| | Insurance, Health | 1 | 2016 | 244 | 0.120 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2014 | 4 | 0.120 |
Why?
| | Ablation Techniques | 1 | 2014 | 29 | 0.120 |
Why?
| | Mitotic Index | 1 | 2014 | 26 | 0.120 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2014 | 38 | 0.110 |
Why?
| | Hyperthermia, Induced | 1 | 2014 | 65 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.110 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 13 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2018 | 535 | 0.110 |
Why?
| | Receptor, ErbB-2 | 1 | 2016 | 300 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3118 | 0.110 |
Why?
| | beta-Galactosidase | 1 | 2013 | 62 | 0.110 |
Why?
| | Breeding | 1 | 2013 | 55 | 0.110 |
Why?
| | Sirolimus | 2 | 2014 | 181 | 0.110 |
Why?
| | Geriatrics | 1 | 2014 | 69 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2013 | 2799 | 0.110 |
Why?
| | Interleukin-2 | 1 | 2014 | 415 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2021 | 984 | 0.110 |
Why?
| | Staining and Labeling | 1 | 2013 | 135 | 0.110 |
Why?
| | Hyperplasia | 1 | 2013 | 165 | 0.110 |
Why?
| | Keratins | 1 | 2013 | 176 | 0.110 |
Why?
| | Urogenital Neoplasms | 1 | 2012 | 5 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2012 | 2191 | 0.110 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 33 | 0.110 |
Why?
| | Organ Specificity | 1 | 2013 | 270 | 0.110 |
Why?
| | Nephrectomy | 2 | 2013 | 150 | 0.110 |
Why?
| | Population Surveillance | 1 | 2015 | 392 | 0.110 |
Why?
| | Adenoviridae | 1 | 2013 | 184 | 0.100 |
Why?
| | Integrases | 1 | 2013 | 116 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 396 | 0.100 |
Why?
| | Celecoxib | 1 | 2012 | 38 | 0.100 |
Why?
| | Thyroid Hormones | 1 | 2012 | 53 | 0.100 |
Why?
| | Thyroid Gland | 1 | 2012 | 83 | 0.100 |
Why?
| | Quinolines | 1 | 2013 | 129 | 0.100 |
Why?
| | RNA, Untranslated | 1 | 2013 | 113 | 0.100 |
Why?
| | Bone Diseases | 1 | 2012 | 57 | 0.100 |
Why?
| | Cross-Over Studies | 3 | 2021 | 441 | 0.100 |
Why?
| | Reoperation | 1 | 2014 | 519 | 0.100 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 218 | 0.100 |
Why?
| | Imidazoles | 1 | 2012 | 209 | 0.100 |
Why?
| | Denosumab | 1 | 2010 | 7 | 0.090 |
Why?
| | PubMed | 1 | 2010 | 11 | 0.090 |
Why?
| | RANK Ligand | 1 | 2010 | 26 | 0.090 |
Why?
| | Animals | 5 | 2016 | 31867 | 0.090 |
Why?
| | Benzenesulfonates | 1 | 2010 | 20 | 0.090 |
Why?
| | Neoplasms | 2 | 2022 | 2106 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2010 | 64 | 0.090 |
Why?
| | Vimentin | 1 | 2010 | 58 | 0.090 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 38 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 697 | 0.090 |
Why?
| | Cell Separation | 1 | 2011 | 291 | 0.090 |
Why?
| | Hypertension | 1 | 2018 | 1058 | 0.090 |
Why?
| | Mesoderm | 1 | 2010 | 138 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 851 | 0.080 |
Why?
| | Cardiovascular Diseases | 2 | 2018 | 1729 | 0.080 |
Why?
| | Cadherins | 1 | 2010 | 175 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 73 | 0.080 |
Why?
| | Age Factors | 1 | 2016 | 2894 | 0.080 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.080 |
Why?
| | Metaplasia | 1 | 2009 | 54 | 0.080 |
Why?
| | Gynecomastia | 1 | 2008 | 4 | 0.080 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 348 | 0.080 |
Why?
| | Risk Factors | 5 | 2018 | 8642 | 0.080 |
Why?
| | Risk | 1 | 2011 | 815 | 0.080 |
Why?
| | Genotype | 1 | 2013 | 1780 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1955 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 955 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1080 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 413 | 0.080 |
Why?
| | Southwestern United States | 1 | 2008 | 91 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 286 | 0.080 |
Why?
| | Liver Failure, Acute | 1 | 2008 | 58 | 0.080 |
Why?
| | Hormone Replacement Therapy | 1 | 2008 | 77 | 0.080 |
Why?
| | Mediastinal Diseases | 1 | 2007 | 10 | 0.070 |
Why?
| | Carcinoid Tumor | 1 | 2007 | 25 | 0.070 |
Why?
| | Pyridines | 1 | 2010 | 426 | 0.070 |
Why?
| | Mice | 2 | 2013 | 14927 | 0.070 |
Why?
| | Glucuronides | 1 | 2006 | 12 | 0.070 |
Why?
| | Neoplasms, Second Primary | 1 | 2008 | 92 | 0.070 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2006 | 74 | 0.070 |
Why?
| | Medical History Taking | 1 | 2007 | 115 | 0.070 |
Why?
| | Excipients | 1 | 2006 | 49 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2006 | 106 | 0.070 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2006 | 98 | 0.070 |
Why?
| | Syndrome | 1 | 2007 | 337 | 0.070 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2006 | 109 | 0.070 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 162 | 0.070 |
Why?
| | Pedigree | 1 | 2007 | 467 | 0.070 |
Why?
| | Everolimus | 2 | 2017 | 61 | 0.060 |
Why?
| | Sarcoidosis | 1 | 2007 | 135 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 827 | 0.060 |
Why?
| | Signal Transduction | 2 | 2016 | 4525 | 0.060 |
Why?
| | Doxorubicin | 1 | 2006 | 285 | 0.060 |
Why?
| | Forecasting | 1 | 2007 | 332 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 324 | 0.060 |
Why?
| | Biomarkers | 2 | 2023 | 3419 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2010 | 956 | 0.060 |
Why?
| | Melanoma | 1 | 2011 | 622 | 0.060 |
Why?
| | DNA Damage | 1 | 2007 | 357 | 0.060 |
Why?
| | Gastrointestinal Diseases | 1 | 2006 | 182 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1355 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2009 | 633 | 0.060 |
Why?
| | Radiotherapy | 2 | 2015 | 176 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 963 | 0.060 |
Why?
| | Young Adult | 4 | 2021 | 10498 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3545 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2015 | 4420 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1634 | 0.050 |
Why?
| | Maximum Tolerated Dose | 2 | 2013 | 183 | 0.050 |
Why?
| | Immune System Diseases | 1 | 2002 | 34 | 0.050 |
Why?
| | Steroid Synthesis Inhibitors | 1 | 2021 | 1 | 0.050 |
Why?
| | Policy | 1 | 2022 | 138 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 82 | 0.050 |
Why?
| | Proteomics | 1 | 2007 | 844 | 0.050 |
Why?
| | Mass Screening | 1 | 2008 | 1012 | 0.050 |
Why?
| | Prednisolone | 1 | 2021 | 76 | 0.050 |
Why?
| | Metabolic Diseases | 1 | 2002 | 98 | 0.050 |
Why?
| | Tumor Burden | 1 | 2021 | 260 | 0.050 |
Why?
| | Bevacizumab | 1 | 2021 | 115 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 331 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 75 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 400 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 358 | 0.040 |
Why?
| | Neovascularization, Pathologic | 1 | 2021 | 281 | 0.040 |
Why?
| | Ytterbium | 1 | 2018 | 2 | 0.040 |
Why?
| | Erbium | 1 | 2018 | 5 | 0.040 |
Why?
| | HLA-A2 Antigen | 1 | 2019 | 37 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 582 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 121 | 0.040 |
Why?
| | Risk Assessment | 1 | 2008 | 2976 | 0.040 |
Why?
| | DNA Methylation | 1 | 2023 | 496 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 11 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 242 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 140 | 0.040 |
Why?
| | Luminescent Measurements | 1 | 2018 | 74 | 0.040 |
Why?
| | Lasers | 1 | 2018 | 121 | 0.040 |
Why?
| | Pain | 1 | 2024 | 709 | 0.040 |
Why?
| | Laparoscopy | 1 | 2021 | 387 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 40 | 0.040 |
Why?
| | Antibodies | 1 | 2018 | 372 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2018 | 201 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1352 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 26 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 91 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 33 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 198 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 117 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 730 | 0.030 |
Why?
| | Nanoconjugates | 1 | 2014 | 1 | 0.030 |
Why?
| | Spectrophotometry, Atomic | 1 | 2014 | 13 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 430 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2018 | 399 | 0.030 |
Why?
| | Lipids | 1 | 2018 | 586 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 123 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 376 | 0.030 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 372 | 0.030 |
Why?
| | Benchmarking | 1 | 2015 | 161 | 0.030 |
Why?
| | Accidental Falls | 1 | 2015 | 150 | 0.030 |
Why?
| | Cell Death | 1 | 2014 | 324 | 0.030 |
Why?
| | Blood Pressure | 1 | 2018 | 1539 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 6232 | 0.020 |
Why?
| | Hydroxamic Acids | 1 | 2012 | 80 | 0.020 |
Why?
| | Health Policy | 1 | 2014 | 334 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2011 | 128 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 198 | 0.020 |
Why?
| | Androgens | 1 | 2011 | 167 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 561 | 0.020 |
Why?
| | Seizures | 1 | 2012 | 341 | 0.020 |
Why?
| | Fatigue | 1 | 2011 | 295 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 1721 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1435 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 275 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 115 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2006 | 83 | 0.020 |
Why?
| | Head and Neck Neoplasms | 1 | 2008 | 427 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1022 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 636 | 0.010 |
Why?
| | Incidence | 1 | 2008 | 2318 | 0.010 |
Why?
|
|
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|